Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 7/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 0.82 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.79 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.76 |
| ▸ | GRK6 | P43250 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090192 | 0.90 | TP53 (1.00) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL9965609 | 0.90 | P4HB (0.81) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL9965528 | 0.90 | MDM2 (0.83) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL23854803 | 0.88 | TP53 (0.82) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL15783085 | 0.88 | TP53 (0.82) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL13836461 | 0.88 | P4HB (1.00) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL9965758 | 0.88 | MDM2 (0.79) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL2153383 | 0.88 | MAPT (0.83) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL21842247 | 0.87 | P4HB (0.77) | P4HBTP53JMJD7CYP2D6CYP2C9 | |
| SCHEMBL15783090 | 0.87 | SMN1; SMN2 (0.81) | P4HBTP53JMJD7CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3079697-B1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY | UNIV CORNELL (US) | 2021-02-03 | — | — | EP | disclosed |
| US-20200360366-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | CORNELL UNIVERSITY (US) | 2020-11-19 | — | — | US | disclosed |
| US-10716783-B2 | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom | CORNELL UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20160317526-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | CORNELL UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015089416-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY | CORNELL UNIVERSITY (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360366-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | ATF4, P4HTM, P4HA1 | P4HB 104/4885TP53 2913/4885JMJD7 2485/4885 |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | P4HB 590/4885TP53 3840/4885JMJD7 2515/4885 |
| US-20160317526-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | HIF1AN, EGLN3, EGLN2 | P4HB 166/4885TP53 2633/4885JMJD7 2274/4885 |
| US-10716783-B2 | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom | HIF1AN, EGLN3, EGLN2 | P4HB 166/4885TP53 2633/4885JMJD7 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.